# Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT

> **NCT07448727** · — · RECRUITING · sponsor: **University of Rome Tor Vergata** · enrollment: 25 (estimated)

## Conditions studied

- Head & Neck Cancer
- Head & Neck Squamous Cell Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07448727
- **Lead sponsor:** University of Rome Tor Vergata
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07448727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07448727, "Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT07448727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*